Alexander Hof: Species-Specific Roles of MPO Deficiency
Alexander Hof, Cardiologist at University Hospital Cologne, North Rhine-Westphalia, Germany, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Redox Biology, adding:
“Delighted to share our latest research on conserved and species-specific effects of Myeloperoxidase deficiency on Neutrophil biology, just published in the field’s leading journal Redox Biology.
11,608 patients were screened to systematically characterize MPO deficiency in humans.
Persistent and transient MPO deficiency differ – persistent deficiency was associated with markedly reduced MPO protein, activity, and plasma levels.
Human and mouse neutrophils share core biological responses, despite substantial species-specific differences.
Different signaling pathways drive similar functions: MAPK/cytokine pathways predominated in humans, while Rho-GTPase signaling was more prominent in mice.
Key translational message: Similar biological outcomes do not necessarily mean identical mechanisms — an important consideration when translating MPO-targeted therapies from animal models to patients.”
Title: Comparative Analysis of Myeloperoxidase Deficiency in Humans and Mice: Conserved and Species-Specific Effects on Neutrophil Biology
Authors: Maysam Ahdab, Henning Guthoff, Nathalie Nix, Sonja Derman, Anna Greta Barbe, Harshal Nemade, Elvina S. Philip, Kezia Singgih, Kathrin Nellessen, Alina Hüttermann, Adnana Paunel-Görgülü, Chris Diekmann, Felix F. Hoyer, Patrick Schelemei, Jan-Wilm Lackmann, Stefan Müller, Wibke Johannis, Thomas Streichert, Stephan Baldus, Holger Winkels, Philipp von Stein, Martin Mollenhauer, Alexander Hof
Stay updated with Hemostasis Today.
-
Oct 16, 2026, 16:01Obi Light Ogbonnia: The Greatest Reward Is Changing Lives, Not Winning Awards
-
Oct 16, 2026, 15:18Carmine Liberatore: Limited Accuracy of VTE Risk Scores in Multiple Myeloma
-
Oct 16, 2026, 14:55Alex Borstein and the Bleeding Phenotype of Hemophilia A Carriers
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy